Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 Cases (1990-1996)

Journal of the American Veterinary Medical Association

Volumn 222, Issue 10, 2003, Pages 1388-1393

  Charney, Sarah C ^a   Bergman, Philip J ^b   Hohenhaus, Ann E ^b   McKnight, Josephine A ^b  

^a Veterinary Teaching Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FUROSEMIDE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BREED; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOG; FEMALE; HEMORRHAGIC CYSTITIS; IMMUNOPATHOLOGY; INCIDENCE; LYMPHOMA; MALE; NEUTROPENIA; NONHUMAN; RETROSPECTIVE STUDY; RISK FACTOR; SEX; TREATMENT OUTCOME; UREMIA; URINARY TRACT INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; CYSTITIS; DIURETICS; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEMORRHAGE; INCIDENCE; INJECTIONS, INTRAVENOUS; LYMPHOMA; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0037950422     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2003.222.1388     Document Type: Article

References (27)

1. Stanton ME, Legendre AM. Effects of cyclophosphamide in dogs and cats. J Am Vet Med Assoc 1986;188:1319-1322.
2. Dhaliwal RS, Kitchell BE. Cyclophosphamide. Compend Contin Educ Vet Pract 1999;21:1059-1063.
3. Plumb DC. Veterinary drug handbook pocket edition. 2nd ed. White Bear Lake, Minn: PharmaVet Publishing, 1995;173-176.
4. Walther MM. Chemical cystitis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997;2725-2729.
5. Teicher BA. Antitumor alkylating agents: pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997;405-415.
6. Peterson JL, Couto CG, Hammer AS, et al. Acute sterile hemorrhagic cystitis after single administration of cyclophosphamide in three dogs. J Am Vet Med Assoc 1992;201:1572-1574.
7. Pearlman CK. Cystitis due to cytoxan: case report. J Urol 1966;95:713-715.
8. deVreis CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol 1990;143:1-9.
9. Weller RE, Wolf AM, Oyejide A. Transitional cell carcinoma of the bladder associated with cyclophosphamide therapy in a dog. J Am Anim Hosp Assoc 1979;15:733-736.
10. Macy DW, Withrow SJ, Hoopes J. Transitional cell carcinoma of bladder associated with cyclophosphamide administration. J Am Anim Hosp Assoc 1983;19:965-968.
11. Henness AM. Treatment of cyclophosphamide induced cystitis. J Am Vet Med Assoc 1985;187:4-5.
12. Crow SE, Theilen GH, Madewell BR, et al. Cyclophosphamide-induced hemorrhagic cystitis in the dog and cat. J Am Vet Med Assoc 1977;171:259-262.
13. Chaviano AH, Gill WB, Ruggiero KJ, et al. Experimental cytoxan cystitis and prevention by acetylcysteine. J Urol 1985;134:598-600.
14. Primack A. Amelioration of cyclophosphamide-induced cystitis. J Natl Cancer Inst 1971;47:223-227.
15. Bryant BM, Jarman M, Fort HT, et al. Prevention of ifosphosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980;2:657-659.
16. Grinberg-Funes DJ, Sheldon C, Weiss M. The use of prostaglandin F2 alpha for the prophylaxis of cyclophosphamide induced cystitis in rats. J Urol 1990;144;1500-1504.
17. Sladek NE, Smith PC, Bratt PM, et al. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity. Cancer Treat Rep 1982;66:1889-1900.
18. Stillwell TJ, Benson RC. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988;61:451-457.
19. Henry CJ, Buss MS, Potter KA, et al. Mitoxantrone and cyclophosphamide combination chemotherapy for the treatment of various canine malignancies. J Am Anim Hosp Assoc 1999;35:236-239.
20. Matus RE. Chemotherapy of lymphoma and leukemia. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders Co, 1989;482-488.
21. Vail DM, MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia:WB Saunders Co, 2001;569.
22. Phillips FS, Sternberg SS, Cronin AP, et al. Cyclo-phosphamide and urinary bladder toxicity. Cancer Res 1961;21:1577-1589.
23. Hill DM. A review of cyclophosphamide. Springfield, Ill; Charles C Thomas Publishers, 1975;172-197.
24. Laing EJ, Miller CW, Cochrane SM. Treatment of cyclophosphamide-induced hemorrhagic cystitis in five dogs. J Am Vet Med Assoc 1988;193:233-236.
25. Bagley CM, Bostick FW, DeVita VT. Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226-233.
26. Lee C, Castles TR, Kintner LD. Single-dose toxicity of cyclophosphamide (NSC-26271) in dogs and monkeys. Cancer Chemother Rep 3 1973;4:51-76.
27. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazide diuretics. Drug Intell Clin Pharm 1981;12:967-970.